Bioanalytical RP‐HPLC Method Development and Validation for Simultaneous Estimation of Temozolomide and Resveratrol: A Pharmacokinetic Analysis in Rat Plasma and Brain
Biomedical Chromatography · 2026-08 · 40 (8)
DOI: 10.1002/bmc.70507 ↗Kurz gefasst
Fachartikel in der Zeitschrift Biomedical Chromatography, online erschienen am 22.06.2026. Verfasst von Saurabh Mittal und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmaceutics, School of Pharmaceutical Education and Research, Jamia Hamdard, New Delhi, India. Hauptthemen laut MEDLINE: Temozolomide, Resveratrol, Chromatography, Reverse-Phase, Brain Chemistry. Die Arbeit nennt 35 Literaturangaben. Gefördert von: ICMR-SRF Research Fellow Saurabh Mittal.
Abstract (Originalsprache)
Temozolomide, a chemotherapy drug used to treat glioblastoma, has high‐dose and dose‐related side effects, limiting its use. Resveratrol, a natural polyphenol, showed potential in the treatment of glioblastoma. Many studies showed the synergistic activity of resveratrol and temozolomide against glioblastoma, but no analytical method for simultaneous estimation in a biological matrix is available till date. This study aimed to develop and validate a simple, rapid, and sensitive bioanalytical method using HPLC technique for simultaneous estimation of temozolomide and resveratrol in rat plasma and brain for pharmacokinetic study. Isocratic reversed‐phase high‐performance liquid chromatography (RP‐HPLC) method using C18 column was used. Theophylline and caffeine were used as internal standards for Temozolomide and Resveratrol, respectively. The mobile phase methanol: 0.1% glacial acetic acid (30:70) with flow rate 1.0 mL/min and 310‐nm wavelength was used. The LOD for temozolomide and resveratrol in the plasma was 0.96 and 1.29 μg/mL, respectively, whereas LOQ was 2.91 and 3.89 μg/mL, respectively. The LOD for temozolomide and resveratrol in brain homogenate was 1.01 and 1.24 μg/mL, respectively, whereas LOQ was 3.07 and 3.76 μg/mL, respectively. This analytical method can be used for simultaneous estimation of temozolomide and resveratrol in biological samples, with higher sensitivity, resulting in more meaningful and appropriate pharmacokinetic analysis.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmaceutics, School of Pharmaceutical Education and Research, Jamia Hamdard, New Delhi, India.
- Department of Pharmaceutics, Amity Institute of Pharmacy, Amity University, Noida, India.
ORCID-Profile: Saurabh Mittal, Javed Ali, Sanjula Baboota
Förderung
- ICMR-SRF Research Fellow Saurabh Mittal
Zitieren
APA
Mittal, S., Ali, J., & Baboota, S. (2026). Bioanalytical RP‐HPLC Method Development and Validation for Simultaneous Estimation of Temozolomide and Resveratrol: A Pharmacokinetic Analysis in Rat Plasma and Brain. Biomedical Chromatography, 40(8). https://doi.org/10.1002/bmc.70507
Vancouver
Mittal S, Ali J, Baboota S. Bioanalytical RP‐HPLC Method Development and Validation for Simultaneous Estimation of Temozolomide and Resveratrol: A Pharmacokinetic Analysis in Rat Plasma and Brain. Biomedical Chromatography. 2026;40(8). doi:10.1002/bmc.70507
BibTeX
@article{Mittal2026,
author = {Mittal, Saurabh and Ali, Javed and Baboota, Sanjula},
title = {Bioanalytical RP‐HPLC Method Development and Validation for Simultaneous Estimation of Temozolomide and Resveratrol: A Pharmacokinetic Analysis in Rat Plasma and Brain},
journal = {Biomedical Chromatography},
year = {2026},
volume = {40},
number = {8},
doi = {10.1002/bmc.70507}
}
EUVIMED